ASX RELEASE 25 SEPTEMBER 2026

EPSILON HEALTHCARE LIMITED

Update to Appendix 4C – Managing Director Loan

Epsilon Healthcare Limited (ACN 614 508 039) (ASX: EPN) (**Epsilon** or the **Company**) refers to its Appendix 4C cash flow reports for the quarters ended 31 December 2025, 31 March 2026 and 30 June 2026.

In Item 7.6 (Financing facilities) of each of those Appendix 4Cs, the Company's Managing Director loan was described as “secured”. EPN clarifies that the loan was at all times unsecured.

No security interest, mortgage, charge or other encumbrance over EPN's assets was granted in connection with the loan.

This update relates only to the description of the loan as “secured” in Item 7.6 of the relevant Appendix 4Cs. It does not affect any financing facility amount, cash flow amount or cash balance previously reported in those Appendix 4Cs, and there has been no change to the underlying security position of the loan.

As the loan was unsecured and no security over EPN's assets was granted in connection with the loan, security holder approval under ASX Listing Rule 10.1 was not required in respect of the loan arrangements.

EPN's Appendix 4D and interim financial report for the half-year ended 30 June 2026 correctly describe the loan as unsecured.

ENDS

This announcement has been unanimously approved for release by the Board of Directors.

Alan Beasley
Chairman

For further information, please contact:
Peter Giannopoulos
Group Chief Executive Officer and Managing Director
e: corporate@epsilonhealthcare.com.au

Epsilon Healthcare Limited (ASX: EPN) – epsilonhealthcare.com.au

Epsilon Healthcare Limited (**ASX: EPN**) is an Australian based, globally active healthcare organisation. EPN operates a diversified and vertically integrated portfolio of assets, including healthcare and clinics operation, pharmaceutical contract development and manufacture, pharmacy and biotechnology therapeutic products.